Dariohealth publishes research confirming the impact of a digital therapeutic platform and live coaching on diabetes outcomes

New york,, may 27, 2021 /prnewswire/ -- dariohealth corp. (nasdaq: drio), a pioneer in the global digital therapeutics market, today announced the publication of a new study through a letter to the editor in the journal of diabetes science and technology. the study is titled "digital therapeutics for type 2 diabetes: incorporating coaching support and validating digital monitoring.
DRIO Ratings Summary
DRIO Quant Ranking